<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02127021</url>
  </required_header>
  <id_info>
    <org_study_id>H-1401-145-552</org_study_id>
    <nct_id>NCT02127021</nct_id>
  </id_info>
  <brief_title>The Effects of High Dose Pancreatic Enzyme Replacement Therapy After Pancreatoduodenectomy</brief_title>
  <official_title>Prospective Study for the Effects of High Dose Pancreatic Enzyme Replacement Therapy on Body Weight, Quality of Life, and Nutritional Assessment After Pancreatoduodenectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pharmbio Korea Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Up to now, the studies concerning nutritional assessment after pancreatic resection were
      rare. The low-dose pancreatic enzyme treatment after pancreatectomy showed no significant
      benefit in terms of nutritional status. This study is a multicenter randomized phase IV study
      by using high-dose Norzyme® (40,000 IU) to evaluate quality of life and nutritional status
      after pancreaticoduodenectomy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There are not enough studies evaluating nutritional parameters in patients with pancreatic
      resection. After pancreatic surgery, there are several ways to improve patient condition in
      terms of quality of life including nutrition.

      In the investigators previous study, pancreatic enzyme supplement through the administration
      of Norzyme® 25000 IU containing lipase 25000 IU, amylase 22500 IU, and protease 1250 IU after
      various type of pancreatectomy to improve quality of life and nutritional status failed to
      prove its effectiveness. After administration of low-dose Norzyme® (25000 IU), some patients
      showed weight gain, but statistically significant conclusions were not obtained mainly
      because of various types of pancreatectomy and low supplementary dosage of pancreatic enzyme.

      Therefore, the investigators design this study to find out the effect of high-dose Norzyme®
      (40000 IU) on weight gain, quality of life, stool habit change, and nutritional status in
      patients with pancreaticoduodenectomy. The investigators will evaluate the effectiveness and
      adequacy of high-dose pancreatic supplementary treatment through a randomized, placebo-using,
      single-blinded, and multicenter study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Actual">December 31, 2017</completion_date>
  <primary_completion_date type="Actual">September 7, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline in body weight at 3 months after medication</measure>
    <time_frame>3 months after medication</time_frame>
    <description>Body weight will be measured 3 times during the entire study period, once preoperatively and two times postoperatively. After surgery, weight will be measured before medication and at the 3 months after medication.These serial weight measurements will be analyzed to figure out changes in body weight over time.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Nutritional Status at 3 months after medication</measure>
    <time_frame>3 months after medication</time_frame>
    <description>To assess the nutritional status of the patient underwent pancreaticoduodenectomy by testing fasting blood glucose, C-peptide, Insulin, Hb A1c, serum protein, serum albumin, serum pre-albumin, and transferrin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in stool habit at 3 months after medication</measure>
    <time_frame>3 months after medication</time_frame>
    <description>To check change from baseline in stool habit at 3 months after medication</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">304</enrollment>
  <condition>Pancreaticoduodenectomy</condition>
  <arm_group>
    <arm_group_label>Norzyme® 40000 IU</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single capsule of Norzyme® 40000 IU will be prescribed three times a day while taking a meal meal.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single capsule of placebo drug with the same appearance of Norzyme® 40000 IU will be prescribed three times a day while taking a meal meal. The formulation and the form of placebo is same with the Norzyme® 40000 IU. Placebo contains microcrystalline cellulose as the main component, titanium oxide, colloidal silica, yellow iron oxide, brown iron oxide, black iron oxide, magnesium stearate, triethyl citrate, talc, and simethicone emulsion in very small amount</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Norzyme® 40000 IU</intervention_name>
    <description>A kind of pancreatic enzyme supplement containing lipase: 40,000 FIP, amylase: 25,000 FIP, and protease: 1,500 FIP Single capsule of Norzyme® 40000 IU will be prescribed three times a day while taking a meal meal</description>
    <arm_group_label>Norzyme® 40000 IU</arm_group_label>
    <other_name>Norzyme</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Single capsule of placebo drug with the same appearance of Norzyme® 40000 IU will be prescribed three times a day while taking a meal meal.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age between 18 and 75 years

          -  ECOG performance status : 0,1,2

          -  Patients who underwent pancreaticoduodenectomy or pylorus preserving
             pancreaticoduodenectomy

          -  stool elastase ≤200, preoperatively and postoperatively

          -  Patients consented to this study

        Exclusion Criteria:

          -  Patients with comorbidities such as liver cirrhosis, chronic renal failure, heart
             failure, and inflammatory bowel disease which can affect the assessment of quality of
             life or nutritional status

          -  Patients underwent major abdominal organ surgery such as gastrectomy and colon
             resection which can affect the assessment of quality of life or nutritional status

          -  Patients with locoregional recurrence or distant metastasis

          -  Patients which were not able to progress diet and medication within 10 days after
             surgery

          -  Patients with pork allergy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jin-Young Jang, M.D., PhD.</last_name>
    <role>Study Chair</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jin-Young Jang, M.D., PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam</city>
        <state>Bundang-gu</state>
        <zip>463-707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Liver Cancer, National Cancer Center</name>
      <address>
        <city>Goyang</city>
        <state>Gyeonggi</state>
        <zip>410-769</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dongguk University Ilsan Medical Center</name>
      <address>
        <city>Goyang</city>
        <state>Kyeonggi</state>
        <zip>410-773</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Surgery, Seoul National University College of Medicine</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chung-Ang University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>156-755</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kangnam Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <study_first_submitted>April 3, 2014</study_first_submitted>
  <study_first_submitted_qc>April 28, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 30, 2014</study_first_posted>
  <last_update_submitted>January 3, 2019</last_update_submitted>
  <last_update_submitted_qc>January 3, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 7, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pancreaticoduodenectomy</keyword>
  <keyword>Nutritional Status</keyword>
  <keyword>Quality of Life</keyword>
  <keyword>Biochemical Marker</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

